Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Buy at Maxim Group

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by equities research analysts at Maxim Group from a “hold” rating to a “buy” rating in a report issued on Friday,Benzinga reports. The firm currently has a $7.00 price objective on the stock. Maxim Group’s target price would indicate a potential upside of 245.68% from the stock’s previous close.

Several other research analysts also recently commented on RVPH. EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $7.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Reviva Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $11.25.

Reviva Pharmaceuticals Stock Up 8.3 %

Shares of Reviva Pharmaceuticals stock traded up $0.16 during trading hours on Friday, hitting $2.03. 1,779,229 shares of the company’s stock traded hands, compared to its average volume of 3,108,544. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.83. The stock has a 50 day simple moving average of $1.54 and a 200-day simple moving average of $1.28. The company has a market cap of $67.72 million, a PE ratio of -1.82 and a beta of -0.12.

Institutional Investors Weigh In On Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.